Evidence map›Paper›PMID 39162649›Full record

Observational studyJournal of radiation research2024

Multi-institutional prospective observational study of radiotherapy for metastatic bone tumor.

Hideyuki Harada, Naoto Shikama, Akifumi Notsu, Hiroki Shirato, Kazunari Yamada, Haruka Uezono, Yutaro Koide, Hikaru Kubota, Takuya Yamazaki, Kei Ito and 19 more

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of radiation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Hideyuki HaradaDivision of Radiation Therapy, Radiation and Proton Therapy Center, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Naoto ShikamaDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Akifumi NotsuClinical Research Center, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Hiroki ShiratoGlobal Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo-shi, Hokkaido, 060-8638, Japan.
Kazunari YamadaDepartment of Radiation Oncology, Seirei Mikatahara General Hospital, 3453 Mikatahara, Chuo-ku, Hamamatsu-shi, Shizuoka, 433-8558, Japan.
Haruka UezonoDepartment of Radiation Oncology, Hyogo Cancer Center, 13-70, Kitaojicho Akashi-shi, Hyogo, 673-0021, Japan.
Yutaro KoideDepartment of Radiation Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya-shi, Aichi, 464-8681, Japan.
Hikaru KubotaDivision of Radiation Oncology, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe-shi, Hyogo, 650-0017, Japan.
Takuya YamazakiDepartment of Radiology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki, 852-8501, Japan.
Kei ItoDepartment of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Joichi HeiannaDepartment of Radiation Oncology, Nanbu Tokushukai Hospital, 171-1 Hokama, Yaese-cho, Shimajiri-gun, Okinawa, 901-0493, Japan.
Yukinori OkadaDepartment of Radiation Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan.
Ayako TonariDepartment of Radiation Oncology, Kyorin University Hospital, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan.
Norio KatohDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo-shi, Hokkaido, 060-8638, Japan.
Hitoshi WadaDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, 7-172 Yatsuyamada, Koriyama-shi, Fukushima, 963-8052, Japan.
Yasuo EjimaDepartment of Radiology, Dokkyo Medical University, 880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi, 321-0293, Japan.
Kayo YoshidaDepartment of Radiology, Keio University School of Medicine, 5 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Takashi KosugiDepartment of Radiation Oncology, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda-shi, Shizuoka, 426-8677, Japan.
Shigeo TakahashiDepartment of Radiation Oncology, Kagawa University Hospital, 1750-1 Ikenobe, Miki, Kita-gun, Kagawa, 761-0793, Japan.
Takafumi KomiyamaDepartment of Radiology, University of Yamanashi, 1110 Shimokato, Chuo-shi, Yamanashi, 409-3898, Japan.
Nobue UchidaDepartment of Radiation Oncology, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo, 108-0073, Japan.
Misako MiwaDepartment of Radiology, Sendai Kousei Hospital, 1-20 sutsumidori, Amemiya, Aoba-ku, Sendai-shi, Miyagi, 981-0914, Japan.
Miho WatanabeDiagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8670, Japan.
Hisayasu NagakuraDepartment of Radiology, KKR Sapporo Medical Center, Hiragishi Ichijo 6-3-40, Toyohira-ku, Sapporo-shi, Hokkaido, 062-0931, Japan.
Hiroko IkedaDepartment of Radiation Oncology, Osaka City General Hospital, 2 Chome-13-22 Miyakojimahondori, Miyakojima-ku, Osaka-shi, Osaka, 534-0021, Japan.
Tetsuo SaitoDepartment of Radiation Oncology, Ariake Medical Center, 2600, Arao, Arao-shi, Kumamoto, 864-0041, Japan.
Isao AsakawaDepartment of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara, 634-8522, Japan.
Takeo TakahashiDepartment of Radiation Oncology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe-shi, Saitama, 350-8550, Japan.
Naoyuki ShigematsuDepartment of Radiology, Keio University School of Medicine, 5 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Funding

Ministry of Health, Labor, and Welfare of Japan 19EA1010Ministry of Health, Labor, and Welfare of Japan 21EA1010
6 · The paper itself

Abstract

Purpose of this study is to evaluate patient characteristics, treatments and outcomes in bone metastasis radiotherapy practice. Patients for whom radiotherapy for bone metastasis was planned at 26 institutions in Japan between December 2020 and March 2021 were consecutively registered in this prospective, observational study. Study measures included patient characteristics, pain relief, skeletal-related events (SREs), overall survival and incidence of radiation-related adverse events. Pain was evaluated using a numerical rating scale (NRS) from 0 to 10. Irradiated dose was analyzed by the biologically effective dose (BED) assuming α/β = 10. Overall, 232 patients were registered; 224 patients and 302 lesions were fully analyzed. Eastern Cooperative Oncology Group Performance Status was 0/1/2/3/4 in 23%/38%/22%/13%/4%; 59% of patients had spinal metastases and 84% had painful lesions (NRS ≥ 2). BED was <20 Gy (in 27%), 20-30 Gy (24%), 30-40 Gy (36%) and ≥ 40 Gy (13%); 9% of patients were treated by stereotactic body radiotherapy. Grade 3 adverse events occurred in 4% and no grade 4-5 toxicity was reported. Pain relief was achieved in 52% at 2 months. BED is not related to pain relief. The cumulative incidence of SREs was 6.5% (95% confidence interval (CI) 3.1-9.9) at 6 months; no factors were significantly associated with SREs. With spinal lesions, 18% of patients were not ambulatory at baseline and 50% of evaluable patients in this group could walk at 2 months. The 6-month overall survival rate was 70.2% (95% CI 64.2-76.9%). In conclusion, we report real-world details of radiotherapy in bone metastasis.

Indexed as

Bone NeoplasmsAdultAgedAged, 80 and overFemaleHumansJapanMaleMiddle AgedPainProspective StudiesRadiotherapy DosageTreatment Outcomebone metastasispain reliefprospective studyradiotherapySRE

Identifiers

PMID39162649
PMCPMC11420848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.